In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

A decision is expected in the fourth quarter of 2025.

Credit: Novo Nordisk. Self-paying patients will now ... “We believe patients living with this chronic disease who want and need treatment under the care of a licensed health care professional ...

US operations and president of Novo Nordisk Inc, in a statement. “We believe patients living with this chronic disease who want and need treatment under the care of a licensed health care ...

In a large study of diabetes, heart failure, or chronic kidney disease patients on renin-angiotensin-aldosterone system (RAAS ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...